Morbus Wilson Treatment - TRIOGEN is now Swissmedic approved and on the SL list!
Non-alcoholic fatty liver disease, NAFLD for short, is a form of fatty liver (steatohepatitis) that is not caused by increased alcohol consumption. It includes both non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). For the diagnosis of NAFLD, significant alcohol consumption (i.e. less than 20 g alcohol per day for men and <10 g/d for women) and other secondary causes of fatty liver (e.g. hepatitis C genotype 3, methotrexate, Sprue, etc.) must be excluded.
Patients with NAFLD have an increased mortality, which is mainly due to cardiovascular diseases, tumor diseases and a progression of the liver disease itself. It should be noted that cardiovascular diseases are a more frequent cause of death in NAFLD than liver-related complications. NAFLD is also considered an independent cardiovascular risk factor and is a predictor for the development of type 2 diabetes. This underlines that the care of patients with fatty liver disease should be multidisciplinary in order to take into account the individual risk profile of the patients (cardiovascular diseases, tumour screening, diabetes, metabolic disorders) and their comorbidities. Consequently, NAFLD should not be considered as an isolated liver disease, but as part of a systemic disease.
Approximately 50% of patients with NAFLD are asymptomatic. The diagnosis is usually made by chance, if elevated levels of transaminases in blood tests or sonography show evidence of fatty liver. NAFLD is also associated with:
50 to 90% of those affected are obese. Patients with NAFLD also show other characteristics of the metabolic syndrome. Some show signs of chronic liver disease (e.g. palmarerythema, spider naevi, splenomegaly). In advanced cases, complications of liver insufficiency (e.g. jaundice, ascites, variceal bleeding) may occur.
There is currently no specific drug therapy approved for NASH or NAFLD. Only HEPACOR (high-dose, purified OMEGA-3) has been shown to make a significant contribution to the complete return to normal liver values with consistent dietary management (see also Condin study).
Therefore, in addition to the regular intake of HEPACOR, the adaptation of lifestyle and the control and therapy of the metabolic syndrome, in particular the treatment of cardiovascular risk factors remain as the cornerstone of therapy. Lifestyle interventions have been proven to be effective. In obese patients, a weight reduction of 10% within one year is sufficient to significantly reduce NAS score and fibrosis stage.
The CONDIN study showed that with early detection,
proper counselling and treatment, liver fat in NAFLD patients was reduced by up to 48% during a 6-month therapy with 3g (4 capsules) HEPACOR® per day. The results indicate that adding HEPACOR® - a highly concentrated and purified Omega-3 - into the dietary management of NAFLD, can reverse the accumulation of a fatty liver in NAFLD patients and inhibit the progression into secondary diseases such as an inflammatory hepatitis (NASH).
HEPACOR® was developed by a medicine scientific research team of BASF.
Copyright © 2018 Ideogen – Alle Rechte vorbehalten.
All the information on our website has been carefully checked and its contents are continually being added to and updated. Nonetheless, although we carefully check the content, we cannot guarantee that it is complete, correct or fully up to date.
COPYRIGHT & TRADEMARKS
The royalty-free use, copying or distribution of this documentation is hereby granted only for non-commercial purposes, provided the copyright notice set out here appears in all copies and both the copyright and this notice of permission appear in supporting documents. Use of the name Ideogen in advertising in connection with the distribution of this documentation requires the specific written permission of Idoegen. All information, documents, and images on this page are the property of the Ideogen and may only be used on this page. Use without prior consent is prohibited.
This website may contain medical and health-related information. This information cannot, however, be considered to be substitute for the advice of a doctor, pharmacist or other health professional, and should not be used for self-diagnosis or the diagnosis of other persons. Scientific data and information regarding development of products or therapies correspond to the situation when they were first published and are therefore subject to change of any kind.
We make every effort to provide you with accurate and up-to-date information. However, Ideogen accepts no responsibility for damage associated with this information or changes to it. For this reason we give neither expressly nor implicitly any warranty or guarantee and provide no assurance in respect of the correctness or completeness of the information provided or referred to. Any use of our website or of any other pages linked to it by means of hyperlinks or their content is at the user's own risk.
Neither Ideogen nor its subsidiaries, nor any other party concerned with the manufacture, provision, design or maintenance of the entire internet offering or individual parts thereof is in any way liable for any immediate or consequential damage, culpable damage or damage regardless of culpability which might arise from access to the internet offering, its use or in particular the inability to use the internet offering of Ideogen or the information provided in connection with it. Ideogen is not responsible for the availability of the websites of third parties or their content. Any use of hyperlinks to these websites is at the user's own risk and implies no liability on the part of Ideogen.
Before the use or application of our products, note should be taken of the related instructions for use. Rights may only be inferred from the instructions included with the products, and not from use of the product information on this website.